Two doses of Pfizer, AstraZeneca shots effective against Delta variant, study finds | Inquirer News

Two doses of Pfizer, AstraZeneca shots effective against Delta variant, study finds

/ 06:23 AM July 22, 2021

Two doses of Pfizer, AstraZeneca shots effective against Delta variant, study finds

FILE PHOTO: Vials with Pfizer-BioNTech and AstraZeneca coronavirus disease (COVID-19) vaccine labels are seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

LONDON Two doses of Pfizer or AstraZeneca’s COVID-19 vaccine are nearly as effective against the highly transmissible Delta coronavirus variant as they are against the previously dominant Alpha variant, a study published on Wednesday showed.

Officials say vaccines are highly effective against the Delta variant, now the dominant variant worldwide, though the study reiterated that one shot of the vaccines is not enough for high protection.

Article continues after this advertisement

The study, published in the New England Journal of Medicine, confirms headline findings given by Public Health England in May about the efficacy of COVID-19 vaccines made by Pfizer-BioNTech and Oxford-AstraZeneca, based on real-world data.

FEATURED STORIES

Wednesday’s study found that two doses of Pfizer’s shot were 88% effective at preventing symptomatic disease from the Delta variant, compared to 93.7% against the Alpha variant, broadly the same as previously reported.

Two shots of the AstraZeneca vaccine were 67% effective against the Delta variant, up from 60% originally reported, and 74.5% effective against the Alpha variant, compared to an original estimate of 66% effectiveness.

Article continues after this advertisement

“Only modest differences in vaccine effectiveness were noted with the Delta variant as compared with the Alpha variant after the receipt of two vaccine doses,” Public Health England (PHE) researchers wrote in the study.

Article continues after this advertisement

Data from Israel has estimated lower effectiveness of Pfizer’s shot against symptomatic disease, although protection against severe disease remains high.

Article continues after this advertisement

PHE had previously said that a first dose of either vaccine was around 33% effective against symptomatic disease from the Delta variant.

The full study published on Wednesday found that one dose of Pfizer’s shot was 36% effective, and one dose of AstraZeneca’s vaccine was around 30% effective.

Article continues after this advertisement

“Our finding of reduced effectiveness after the first dose would support efforts to maximize vaccine uptake with two doses among vulnerable groups in the context of circulation of the Delta variant,” the authors of the study said.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: AstraZeneca, COVID-19, efficacy, Pfizer, vaccine

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.